PXD043340

PXD043340 is an original dataset announced via ProteomeXchange.

Title	Plasma ALS and LG3BP predict liver fibrosis in NAFLD patients
Description	Non-alcoholic fatty liver disease (NAFLD) is estimated to affect 25% of the world’s population and its prevalence is increasing with the rise in obesity. The evolution of this disease includes different pathological stages: steatosis, inflammation, fibrosis, cirrhosis and hepatocellular carcinoma (HCC). Liver biopsy stands as the gold standard for NAFLD assessment despite its invasive nature and limited performance. Liver fibrosis is the most important clinical parameter, as it is closely related to mortality, and biopsies are only considered when advanced fibrosis is suspected. This scenario makes the finding of a non-invasive and reliable biomarker an urgent need for an accurate diagnosis. To this end, we first performed a discovery study on 159 plasma samples from histologically characterised NAFLD patients using mass spectrometry (MS)-based quantitative proteomics. Insulin-like growth factor-binding protein complex acid labile (ALS, P35858) and Galectin-3-binding protein (LG3BP, Q08380) were selected for a verification by enzyme-linked immunosorbent assay (ELISA) in the same cohort and finally validated in an independent NAFLD cohort of 200 plasma samples.ALS and LG3BP were validated as advanced liver fibrosis biomarkers and successfully included in a panel with FibroTest variables. ELISA kits availability would allow to achieve relatively fast clinical translation if further investigations in larger cohorts confirm these results.
HostingRepository	PRIDE
AnnounceDate	2024-05-22
AnnouncementXML	Submission_2024-05-22_13:42:36.782.xml
DigitalObjectIdentifier	https://dx.doi.org/10.6019/PXD043340
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Supported dataset by repository
PrimarySubmitter	Hesse Anne-Marie
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	acetylated residue; monohydroxylated residue; iodoacetamide derivatized residue
Instrument	Q Exactive HF

Revision	Datetime	Status	ChangeLog Entry
0	2023-06-27 06:42:42	ID requested
⏵ 1	2024-05-22 13:42:37	announced

10.1186/s40364-024-00583-z;

10.6019/PXD043340;

P, é, rez Compte D, Etourneau L, Hesse AM, Kraut A, Barthelon J, Sturm N, Borges H, Biennier S, Cour, ç, on M, de Saint Loup M, Mignot V, Costentin C, Burger T, Cout, é Y, Bruley C, Decaens T, Jaquinod M, Boursier J, Brun V, Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients. Biomark Res, 12(1):44(2024) [pubmed]

submitter keyword: plasma NAFLD biomarkers discovery

Yohann Couté
contact affiliation	Univ. Grenoble Alpes, INSERM, CEA, UMR BioSanté U1292, CNRS, CEA, FR2048 ProFI, 38000 Grenoble, France
contact email	yohann.coute@cea.fr
lab head
Hesse Anne-Marie
contact affiliation	Laboratoire d'Etude de la Dynamique des Protéomes
contact email	anne-marie.hesse@cea.fr
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2024/05/PXD043340

PRIDE project URI

• PRIDE
  1. PXD043340
     1. Label: PRIDE project
     2. Name: Plasma ALS and LG3BP predict liver fibrosis in NAFLD patients